Treatment Resistant Cancers
Targeted Cancer Therapies
Cancer Therapies
Combination Therapies and Personalized Medicine
Tumor Immunotherapy
Cancer Survival Analysis
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Aug 14, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
H K van Halteren1, J Bennouna2, B Brasiuniene3
1Department of Medical Oncology, Adrz Hospital, Goes, The Netherlands.
Medical oncologists need clear data on cancer trial benefits versus treatment burden. This review of ESMO 2022 presentations highlights the need for better reporting of progression-free survival (PFS) and overall survival (OS) data to ensure sustainable cancer care.
Area of Science:
Background: